<p><strong>Geriatrics ( 65 years of age)</strong>: There were no overall differences in safety and effectiveness of Roflumilast in the elderly compared to younger patients with COPD. Therefore, no dose adjustment is necessary.<br />
<br />
<strong>Pediatrics (&lt;18 years of age)</strong>: Safety and effectiveness of Roflumilast in children and adolescents below 18 years of age have not been established.<br />
<br />
<strong>Hepatic Impairment</strong>: Roflumilast is not recommended for use in patients with moderate or severe liver impairment.<br />
<br />
<strong>Renal impairment</strong>: No dosage adjustment is necessary for patients with renal impairment</p>